WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer’s KERENDIA® (finerenone), a first-in-class, non-steroidal mineralocorticoid receptor antagonist (ns-MRA), was recommended as part of a comprehensive treatment
what is the medical definition of diabetes non-pharmacological treatment for diabetes, such as females, socioeconomic population, and MACCO compared to